325 related articles for article (PubMed ID: 31081391)
21. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.
Joffe H; Guthrie KA; LaCroix AZ; Reed SD; Ensrud KE; Manson JE; Newton KM; Freeman EW; Anderson GL; Larson JC; Hunt J; Shifren J; Rexrode KM; Caan B; Sternfeld B; Carpenter JS; Cohen L
JAMA Intern Med; 2014 Jul; 174(7):1058-66. PubMed ID: 24861828
[TBL] [Abstract][Full Text] [Related]
22. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women.
Weber L; Thacker HL
Womens Health (Lond); 2014 Mar; 10(2):147-54. PubMed ID: 24601805
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.
Freeman EW; Guthrie KA; Caan B; Sternfeld B; Cohen LS; Joffe H; Carpenter JS; Anderson GL; Larson JC; Ensrud KE; Reed SD; Newton KM; Sherman S; Sammel MD; LaCroix AZ
JAMA; 2011 Jan; 305(3):267-74. PubMed ID: 21245182
[TBL] [Abstract][Full Text] [Related]
24. [HTA and non-hormonal menopause treatment].
Boivin JM
Presse Med; 2019 Nov; 48(11 Pt 1):1284-1287. PubMed ID: 31473025
[TBL] [Abstract][Full Text] [Related]
25. Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Albertazzi P
J Br Menopause Soc; 2006 Mar; 12(1):7-11. PubMed ID: 16513016
[TBL] [Abstract][Full Text] [Related]
26. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms.
Umland EM
J Manag Care Pharm; 2008 Apr; 14(3 Suppl):14-9. PubMed ID: 18439062
[TBL] [Abstract][Full Text] [Related]
27. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.
Stearns V; Beebe KL; Iyengar M; Dube E
JAMA; 2003 Jun; 289(21):2827-34. PubMed ID: 12783913
[TBL] [Abstract][Full Text] [Related]
28. EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms.
Mintziori G; Lambrinoudaki I; Goulis DG; Ceausu I; Depypere H; Erel CT; Pérez-López FR; Schenck-Gustafsson K; Simoncini T; Tremollieres F; Rees M
Maturitas; 2015 Jul; 81(3):410-3. PubMed ID: 25982505
[TBL] [Abstract][Full Text] [Related]
29. Clinical Inquiry: Which nonhormonal treatments are effective for hot flashes?
Kelsberg G; Maragh L; Safranek S
J Fam Pract; 2016 May; 65(5):E1-3. PubMed ID: 27275942
[TBL] [Abstract][Full Text] [Related]
30. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network.
Joffe H; Guthrie KA; Larson J; Cohen LS; Carpenter JS; Lacroix AZ; Freeman EW
Menopause; 2013 Mar; 20(3):261-8. PubMed ID: 23435022
[TBL] [Abstract][Full Text] [Related]
31. Therapy: nonhormonal treatment of hot flashes-a viable alternative?
Nachtigall LE
Nat Rev Endocrinol; 2010 Feb; 6(2):66-7. PubMed ID: 20098445
[TBL] [Abstract][Full Text] [Related]
32. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions.
Johns C; Seav SM; Dominick SA; Gorman JR; Li H; Natarajan L; Mao JJ; Irene Su H
Breast Cancer Res Treat; 2016 Apr; 156(3):415-426. PubMed ID: 27015968
[TBL] [Abstract][Full Text] [Related]
33. The 2023 nonhormone therapy position statement of The North American Menopause Society.
“The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory Panel
Menopause; 2023 Jun; 30(6):573-590. PubMed ID: 37252752
[TBL] [Abstract][Full Text] [Related]
34. Managing menopausal symptoms after cancer.
Szabo RA; Marino JL; Hickey M
Climacteric; 2019 Dec; 22(6):572-578. PubMed ID: 31433675
[TBL] [Abstract][Full Text] [Related]
35. Non-hormonal treatment strategies for vasomotor symptoms: a critical review.
Hall E; Frey BN; Soares CN
Drugs; 2011 Feb; 71(3):287-304. PubMed ID: 21319867
[TBL] [Abstract][Full Text] [Related]
36. Beyond Estrogen: Treatment Options for Hot Flashes.
McGarry K; Geary M; Gopinath V
Clin Ther; 2018 Oct; 40(10):1778-1786. PubMed ID: 30217591
[TBL] [Abstract][Full Text] [Related]
37. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2004; 11(1):11-33. PubMed ID: 14716179
[TBL] [Abstract][Full Text] [Related]
38. New generation nonhormonal management for hot flashes.
Imai A; Matsunami K; Takagi H; Ichigo S
Gynecol Endocrinol; 2013 Jan; 29(1):63-6. PubMed ID: 22809093
[TBL] [Abstract][Full Text] [Related]
39. Managing menopausal symptoms after cancer: an evidence-based approach for primary care.
Marino JL; McNamara HC; Hickey M
Med J Aust; 2018 Feb; 208(3):127-132. PubMed ID: 29438648
[TBL] [Abstract][Full Text] [Related]
40. Treatment options for vasomotor symptoms in menopause: focus on desvenlafaxine.
Umland EM; Falconieri L
Int J Womens Health; 2012; 4():305-19. PubMed ID: 22870045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
